English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
TürkçeAdaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Adaptive Biotechnologies (ADPT) reported $71.68 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 51%. EPS of -$0.09 for the same period compares to -$0.23 a year ago.
The reported revenue represents a surprise of -0.44% over the Zacks Consensus Estimate of $72 million. With the consensus EPS estimate being -$0.19, the EPS surprise was +52.63%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: ClonoSEQ test volume: 30,038 versus 28,950 estimated by three analysts on average. Revenue- Total MRD: $61.89 million versus the three-analyst average estimate of $54.78 million. The reported number represents a year-over-year change of +54.1%. Revenue- Total Immune Medicine: $9.79 million versus the three-analyst average estimate of $3.92 million. The reported number represents a year-over-year change of +34%.View all Key Company Metrics for Adaptive Biotechnologies here>>>
Shares of Adaptive Biotechnologies have returned +3.4% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).